N4 PHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.625 GBX | -3.85% |
|
-12.59% | -26.47% |
| Apr. 25 | N4 Pharma strikes partnership deal for intracellular delivery | AN |
| Apr. 23 | N4 Pharma loss widens but "great optimism" remains | AN |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 8.505 | 2.79 | 15.12 | 8.058 | 4.325 | 2.285 |
| Enterprise Value (EV) 1 | 7.748 | 1.84 | 11.56 | 6.274 | 2.405 | 1.258 |
| P/E ratio | -7.06 x | -3.14 x | -8.72 x | -5.22 x | -3.35 x | -1.63 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 117 x | - | - | - | - | 1,170 x |
| EV / Revenue | 106 x | - | - | - | - | 644 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | -7.76 x | -3.65 x | -11.3 x | -4.55 x | -4.42 x | -1.53 x |
| FCF Yield | -12.9% | -27.4% | -8.89% | -22% | -22.6% | -65.5% |
| Price to Book | 9.67 x | 2.83 x | 4.13 x | 3.78 x | 2.07 x | 2.03 x |
| Nbr of stocks (in thousands) | 90,963 | 101,463 | 181,080 | 181,080 | 233,780 | 268,780 |
| Reference price 2 | 0.0935 | 0.0275 | 0.0835 | 0.0445 | 0.0185 | 0.008500 |
| Announcement Date | 5/17/19 | 3/1/20 | 2/25/21 | 2/24/22 | 3/8/23 | 4/23/24 |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.0728 | - | - | - | - | 0.001953 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -1.417 | -0.9473 | -1.564 | -1.843 | -1.193 | -1.425 |
| Operating Margin | -1,945.7% | - | - | - | - | -72,943.88% |
| Earnings before Tax (EBT) 1 | -1.39 | -0.9487 | -1.566 | -1.843 | -1.193 | -1.425 |
| Net income 1 | -1.185 | -0.8764 | -1.305 | -1.544 | -1.029 | -1.269 |
| Net margin | -1,626.82% | - | - | - | - | -64,993.91% |
| EPS 2 | -0.0132 | -0.008749 | -0.009573 | -0.008528 | -0.005521 | -0.005225 |
| Free Cash Flow 1 | -0.999 | -0.504 | -1.028 | -1.379 | -0.5448 | -0.8236 |
| FCF margin | -1,371.63% | - | - | - | - | -42,172.56% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/17/19 | 3/1/20 | 2/25/21 | 2/24/22 | 3/8/23 | 4/23/24 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 0.76 | 0.95 | 3.56 | 1.78 | 1.92 | 1.03 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -1 | -0.5 | -1.03 | -1.38 | -0.54 | -0.82 |
| ROE (net income / shareholders' equity) | -110% | -93.9% | -56.2% | -53.4% | -48.8% | -77.8% |
| ROA (Net income/ Total Assets) | -70% | -55.5% | -40% | -37.4% | -33.1% | -51.7% |
| Assets 1 | 1.692 | 1.58 | 3.264 | 4.135 | 3.111 | 2.453 |
| Book Value Per Share 2 | 0.0100 | 0.0100 | 0.0200 | 0.0100 | 0.0100 | 0 |
| Cash Flow per Share 2 | 0.0100 | 0.0100 | 0.0200 | 0.0100 | 0.0100 | 0 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 5/17/19 | 3/1/20 | 2/25/21 | 2/24/22 | 3/8/23 | 4/23/24 |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -26.47% | 2.14M | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- ONZ Stock
- Financials N4 Pharma Plc
